OVERVIEW OF REGULATION OF GENE-THERAPY IN EUROPE - A CURRENT STATEMENT INCLUDING REFERENCE TO US REGULATION

被引：13

作者：

COHENHAGUENAUER, O ^{[1
]}

机构：

[1] HOP ST LOUIS,EWGT CENT OFF,F-75475 PARIS 10,FRANCE

来源：

关键词：

D O I：

10.1089/hum.1995.6.6-773

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：773 / 785

页数：13

共 25 条

[11]

OSTROVE JM, 1994, IN PRESS CANCER GENE, V1

OTTO, E ;

JONESTROWER, A ;

VANIN, EF ;

STAMBAUGH, K ;

MUELLER, SN ;

ANDERSON, WF ;

MCGARRITY, GJ .

[13]

SCOTT SR, 1993, BIOL DEV REGULATORY, P7

[14]

TEMIM HM, 1990, HUM GENE THER, V1, P11

[15]

ZORZIMORRE P, 1992, RECENT ADV PHARM IND

[16]

1991, POINTS CONSIDER HUMA

[17]

1993, APPLICATION CURRENT

[18]

1985, POINTS CONSIDER PROD

[19]

1986, RECOMBINANT DNA SAFE

[20]

1989, J BIOL STAND, V17, P203